A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug ...

For many years, doctors have struggled because pancreatic cancer usually causes few symptoms in its early stages. By the time ...

An investigational targeted therapy designed to block one of the most common genetic drivers of pancreatic cancer has shown ...

The KRAS p.G12D variant occurs in 5% of patients with non–small-cell lung cancer (NSCLC) and is the most common substitution variant in pancreatic ductal adenocarcinoma, occurring in 40% of patients, ...

Structural insight into KRAS conformational cycling exposed temporary binding opportunities, overturning the “undruggable” paradigm and enabling inhibitors that engage previously hidden pockets.